Periodic surveillance of intraductal papillary mucinous neoplasms: gaps in evidence and future directions

Clicks: 4
ID: 320671
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #43 of 329 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 329 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Intraductal papillary mucinous neoplasm (IPMN) is a well-established precursor to pancreatic cancer; however, its generally indolent biological behavior necessitates prolonged periodic surveillance in most patients. This review synthesizes current evidence and highlights unmet needs, while providing future perspectives on the clinical management of patients with IPMNs. In contrast to the relatively robust evidence regarding predictive factors for prevalent pancreatic carcinoma, substantial clinical and research gaps remain in periodic surveillance strategies for IPMN. Despite multiple international guidelines, unified risk-stratified surveillance protocols have yet to be established, particularly with respect to imaging modalities, surveillance intervals, and criteria for surveillance discontinuation. This lack of agreement is attributable, in part, to the paucity of large-scale longitudinal cohorts needed to develop robust risk prediction models. An additional challenge is the risk of carcinoma developing concomitantly with IPMN, which often progresses more rapidly with fewer appreciable early morphological changes than carcinoma derived from IPMN. Future research should focus on developing comprehensive risk stratification schemes based on large prospective cohorts to establish evidence-based criteria for surveillance intervals and discontinuation criteria. These efforts should also take into account the surveillance-related burden on patients and healthcare systems, including psychological distress and financial costs, as well as strategies for early detection of concomitant pancreatic carcinoma. Furthermore, integration of advanced biomarkers and artificial intelligence-based models is warranted.
Reference Key
openalex_W7168026794 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Tsuyoshi Hamada, Hiroki Oyama, Yousuke Nakai, Maxim S. Petrov
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag225
URL
https://doi.org/10.1093/jnci/djag225
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.